{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05700903",
            "orgStudyIdInfo": {
                "id": "22-2201.cc"
            },
            "organization": {
                "fullName": "University of Colorado, Denver",
                "class": "OTHER"
            },
            "briefTitle": "Contributions to Hypertension With Androgen Deprivation Therapy",
            "officialTitle": "Autonomic and Renal Contributions to Hypertension With Androgen Deprivation Therapy",
            "acronym": "ARCH",
            "therapeuticArea": [
                "Cardiovascular",
                "Oncology and Hematology",
                "Other",
                "Nephrology and Renal Diseases"
            ],
            "study": "contributions-to-hypertension-with-androgen-deprivation-therapy"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-09-20",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2028-03-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2028-03-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-01-10",
            "studyFirstSubmitQcDate": "2023-01-18",
            "studyFirstPostDateStruct": {
                "date": "2023-01-26",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-10",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-12",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "University of Colorado, Denver",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This study plans to learn more about contributors to high blood pressure in men who undergo androgen deprivation therapy (ADT) to treat prostate cancer. Prostate cancer is the most common non-skin cancer in men, affecting approximately 1 in 8 American men and its primary treatment is through the use of ADT. However, ADT increases the likelihood of developing heart disease including high blood pressure. This study will determine if dysfunction of the nervous system and/or kidneys occurs in men undergoing ADT, as these systems play a significant role in control of blood pressure. The results from this study will help us understand the ways in which ADT contributes to heart disease and help us develop therapies to prevent heart disease in prostate cancer survivors."
        },
        "conditionsModule": {
            "conditions": [
                "Androgen Deprivation Therapy",
                "Prostate Cancer",
                "Hypertension",
                "Autonomic Dysfunction",
                "Renal Disease"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE4"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "BASIC_SCIENCE",
                "maskingInfo": {
                    "masking": "TRIPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 228,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Prostate Cancer",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Men undergoing androgen deprivation therapy via gonadotropin releasing hormone agonist plus androgen receptor inhibitor for the treatment of prostate cancer",
                    "interventionNames": [
                        "Drug: Gonadotropin Releasing Hormone Agonists (GNRH)",
                        "Drug: Androgen receptor (AR) inhibitor"
                    ]
                },
                {
                    "label": "Healthy + ADT",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Healthy men undergoing gonadal suppression via gonadotropin releasing hormone agonist plus androgen receptor inhibitor for 9 weeks",
                    "interventionNames": [
                        "Drug: Gonadotropin Releasing Hormone Agonists (GNRH)",
                        "Drug: Androgen receptor (AR) inhibitor"
                    ]
                },
                {
                    "label": "Healthy + Placebo",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Healthy men undergoing placebo for 9 weeks.",
                    "interventionNames": [
                        "Drug: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Gonadotropin Releasing Hormone Agonists (GNRH)",
                    "description": "8 weeks of GnRH agonist",
                    "armGroupLabels": [
                        "Healthy + ADT",
                        "Prostate Cancer"
                    ],
                    "otherNames": [
                        "Leuprolide",
                        "Goserelin"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Androgen receptor (AR) inhibitor",
                    "description": "2 weeks of AR Inhibitor",
                    "armGroupLabels": [
                        "Healthy + ADT",
                        "Prostate Cancer"
                    ],
                    "otherNames": [
                        "Bicalutamide",
                        "Flutamide",
                        "Enzalutamide"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "Placebo tablet and injection",
                    "armGroupLabels": [
                        "Healthy + Placebo"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Change in Cardiovagal Baroreflex Sensitivity",
                    "description": "The change in cardiovagal baroreflex sensitivity will be assessed the modified Oxford procedure",
                    "timeFrame": "Before and after 9 weeks of androgen deprivation therapy or placebo"
                },
                {
                    "measure": "Change in blood pressure reactivity to the cold pressor test",
                    "description": "The change in blood pressure will be assessed from quiet rest to sympathetic activation using the cold pressor test",
                    "timeFrame": "Before and after 9 weeks of androgen deprivation therapy or placebo"
                },
                {
                    "measure": "Change in exercise pressor reflex",
                    "description": "The change in blood pressure will be assessed from quiet rest to isometric handgrip exercise",
                    "timeFrame": "Before and after 9 weeks of androgen deprivation therapy or placebo"
                },
                {
                    "measure": "Change in ambulatory blood pressure variability",
                    "description": "Ambulatory blood pressure variability will be determined from 24-hour ambulatory blood pressure monitoring.",
                    "timeFrame": "Before and after 9 weeks of androgen deprivation therapy or placebo"
                },
                {
                    "measure": "Change in beat-to-beat blood pressure variability",
                    "description": "Beat-to-beat blood pressure variability will be using finger photoplethysmography measured in the laboratory.",
                    "timeFrame": "Before and after 9 weeks of androgen deprivation therapy or placebo"
                },
                {
                    "measure": "Change in renal vascular resistance",
                    "description": "Renal blood flow will be determined using ultrasound and blood pressure will be determined using finger photoplethysmography. These measures will be used to estimate renal vascular resistance.",
                    "timeFrame": "Before and after 9 weeks of androgen deprivation therapy or placebo"
                },
                {
                    "measure": "Change in Renal dysfunction biomarkers",
                    "description": "Neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule (KIM)-1, interleukin (IL)-18, and vanin-1 will be quantified in urine using commercially available assay kits. Concentrations will be normalized to urinary flow rate.",
                    "timeFrame": "Before and after 9 weeks of androgen deprivation therapy or placebo"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Change in sympathetic baroreflex sensitivity",
                    "description": "Changes in muscle sympathetic nerve activity in response to changes in blood pressure will be assessed using the modified Oxford procedure",
                    "timeFrame": "Before and after 9 weeks of androgen deprivation therapy or placebo"
                },
                {
                    "measure": "Change in Sympathetic reactivity",
                    "description": "The change in muscle sympathetic nerve activity will be assessed from quiet rest to sympathetic activation using the cold pressor test.",
                    "timeFrame": "Before and after 9 weeks of androgen deprivation therapy or placebo"
                },
                {
                    "measure": "Change in glomerular filtration rate",
                    "description": "Glomerular filtration rate and renal plasma flow will be calculated by iohexol (Omnipaque 300, GE Healthcare) clearance technique. Plasma and urine iohexol and p-aminohippurate clearance will be measured on a High-Performance Liquid Chromatography (HPLC, Waters, Milford, MA).",
                    "timeFrame": "Before and after 9 weeks of androgen deprivation therapy or placebo"
                },
                {
                    "measure": "Change in renal plasma flow",
                    "description": "Renal plasma flow will be calculated by p-aminohippurate (Basic Pharma) clearance techniques. Plasma and urine p-aminohippurate clearance will be measured on a High-Performance Liquid Chromatography (HPLC, Waters, Milford, MA).",
                    "timeFrame": "Before and after 9 weeks of androgen deprivation therapy or placebo"
                }
            ],
            "otherOutcomes": [
                {
                    "measure": "Change in Inflammation",
                    "description": "Proteomic analysis of inflammatory cascade proteins will be quantified in plasma samples.",
                    "timeFrame": "Before and after 9 weeks of androgen deprivation therapy or placebo"
                },
                {
                    "measure": "Change in Oxidative stress",
                    "description": "Whole blood reactive oxygen species will be measured in from venous blood samples using electron paramagnetic resonance spectroscopy",
                    "timeFrame": "Before and after 9 weeks of androgen deprivation therapy or placebo"
                },
                {
                    "measure": "Change in Body composition",
                    "description": "Descriptive variable total body fat mass (for screening and to document any changes with the intervention)",
                    "timeFrame": "Before and after 9 weeks of androgen deprivation therapy or placebo"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* -age 40+ years;\n* resting blood pressure \\<140/90 mmHg;\n* fasted blood glucose \\<126 mg/dL;\n* testosterone \u2265400 ng/dL;\n* sedentary to recreationally active;\n* nonsmokers;\n* healthy as determined by medical history, physical exam, blood and urine chemistries and resting and exercise ECG during a physician supervised graded exercise treadmill test OR recent diagnosis of non-metastatic prostate cancer with plans to undergo androgen deprivation therapy;\n* PSA \\<4.00 ng/dL if in the non-cancer group;\n* Gleason Score \u22647 if in the prostate cancer group;\n* no use of medications that might influence cardiovascular function (e.g., antihypertensives, lipid-lowering medications);\n* willing and able to be on GnRHagonist and AR inhibitor;\n* not taking antioxidant vitamins, corticosteroids, or anti-inflammatory medications, or willing to stop use for four weeks prior to the start of the study;\n* not using exogenous sex hormones for at least one year\n\nExclusion Criteria:\n\n* -acute liver disease;\n* chronic kidney disease, serum creatinine \\>1.3 mg/dL, macroalbuminuria \\>300 mg/g of proteinuria\n* pre-existing or active cardiac, renal or hepatic disease, epilepsy or other seizure disorder;\n* diabetes, active or chronic infection, disease that affects the nervous system;\n* Gleason Score \u22658;\n* thyroid dysfunction, defined as ultrasensitive TSH \\<0.5 or \\>5.0 mU/L, volunteers with abnormal TSH values will be re-considered for participation after follow-up evaluation by the PCP with initiation or adjustment of thyroid hormone replacement;\n* tobacco use within the previous 12 months",
            "healthyVolunteers": true,
            "sex": "MALE",
            "minimumAge": "40 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Matthew Babcock, PhD",
                    "role": "CONTACT",
                    "phone": "303-724-1401",
                    "email": "matthew.babcock@cuanschutz.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Matthew Babcock, PhD",
                    "affiliation": "University of Colorado - Anschutz Medical Campus",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "UCHealth University of Colorado Hospital",
                    "status": "RECRUITING",
                    "city": "Aurora",
                    "state": "Colorado",
                    "zip": "80045",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Matthew Babcock, PhD",
                            "role": "CONTACT",
                            "phone": "720-848-6470",
                            "email": "matthew.babcock@cuanschutz.edu"
                        },
                        {
                            "name": "Matthew Babcock, PhD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.72943,
                        "lon": -104.83192
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000001342",
                    "term": "Autonomic Nervous System Diseases"
                },
                {
                    "id": "D000054969",
                    "term": "Primary Dysautonomias"
                },
                {
                    "id": "D000006973",
                    "term": "Hypertension"
                }
            ],
            "ancestors": [
                {
                    "id": "D000014652",
                    "term": "Vascular Diseases"
                },
                {
                    "id": "D000002318",
                    "term": "Cardiovascular Diseases"
                },
                {
                    "id": "D000009422",
                    "term": "Nervous System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M10698",
                    "name": "Kidney Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14335",
                    "name": "Prostatic Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M10024",
                    "name": "Hypertension",
                    "asFound": "Hypertension",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4643",
                    "name": "Autonomic Nervous System Diseases",
                    "asFound": "Autonomic Dysfunction",
                    "relevance": "HIGH"
                },
                {
                    "id": "M27979",
                    "name": "Primary Dysautonomias",
                    "asFound": "Autonomic Dysfunction",
                    "relevance": "HIGH"
                },
                {
                    "id": "M17400",
                    "name": "Vascular Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC14",
                    "name": "Heart and Blood Diseases"
                },
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000016729",
                    "term": "Leuprolide"
                },
                {
                    "id": "D000017273",
                    "term": "Goserelin"
                },
                {
                    "id": "D000005485",
                    "term": "Flutamide"
                },
                {
                    "id": "C000053541",
                    "term": "Bicalutamide"
                },
                {
                    "id": "D000006728",
                    "term": "Hormones"
                },
                {
                    "id": "D000000728",
                    "term": "Androgens"
                }
            ],
            "ancestors": [
                {
                    "id": "D000006730",
                    "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000005300",
                    "term": "Fertility Agents, Female"
                },
                {
                    "id": "D000005299",
                    "term": "Fertility Agents"
                },
                {
                    "id": "D000012102",
                    "term": "Reproductive Control Agents"
                },
                {
                    "id": "D000018931",
                    "term": "Antineoplastic Agents, Hormonal"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000000726",
                    "term": "Androgen Antagonists"
                },
                {
                    "id": "D000006727",
                    "term": "Hormone Antagonists"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M19090",
                    "name": "Leuprolide",
                    "asFound": "Strain",
                    "relevance": "HIGH"
                },
                {
                    "id": "M19568",
                    "name": "Goserelin",
                    "asFound": "Participating",
                    "relevance": "HIGH"
                },
                {
                    "id": "M231527",
                    "name": "Bicalutamide",
                    "asFound": "Closed-loop",
                    "relevance": "HIGH"
                },
                {
                    "id": "M9789",
                    "name": "Hormones",
                    "asFound": "Clinic",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4059",
                    "name": "Androgens",
                    "asFound": "Percutaneous Coronary Intervention",
                    "relevance": "HIGH"
                },
                {
                    "id": "M8612",
                    "name": "Flutamide",
                    "asFound": "Epicardial",
                    "relevance": "HIGH"
                },
                {
                    "id": "M29347",
                    "name": "Androgen Receptor Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M9788",
                    "name": "Hormone Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M20966",
                    "name": "Antineoplastic Agents, Hormonal",
                    "relevance": "LOW"
                },
                {
                    "id": "M4057",
                    "name": "Androgen Antagonists",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "Repr",
                    "name": "Reproductive Control Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}